News

CVS to boost access to Novo Nordisk's weight loss treatment Wegovy for patients on its drug plans
CVS Health said it will significantly expand access to Novo Nordisk's blockbuster weight loss drug Wegovy for patients ...
Healthcare Dive2d
CVS plans to exit ACA individual exchanges, strikes Wegovy deal with Novo Nordisk
Aetna is once again retreating from the Affordable Care Act market, while its parent company notched a deal with Danish ...
Lilly star weight-loss drug Zepbound faces coverage challenge from CVS Health
Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...
Managed Healthcare Executive2d
CVS Caremark to Place Wegovy as Preferred GLP-1 for Weight Loss
Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.
Fierce Pharma2d
In major blow for Lilly, Novo strikes deal giving Wegovy preferred access on CVS Caremark formulary
Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...
CVS Stock Climbs After Wegovy Deal, Strong 1Q
Shares of CVS Health jumped after the company reported a strong first quarter and agreed to open up access to Novo Nordisk's weight-loss medication at more affordable prices. The stock was up 8.7% at ...
CVS drops Zepbound from preferred coverage in major blow to Eli Lilly
CVS said it will expand access to blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, Caremark.
Eli Lilly downplays CVS move to drop Zepbound coverage, shares plunge
Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...